Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor - Seite 3

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

# # #

Novartis Media Relations

Central media line : [phone]
Eric Althoff Novartis Global Media Relations [phone] (direct) [phone] (mobile) [e-mail]	Jeff Lockwood Novartis Institutes for BioMedical Research + 1 617 871 7026 (direct) + 1 617 510 6997 (mobile) [e-mail]

e-mail: [e-mail]

Novartis Investor Relations

Central phone:	[phone]	North America:
Samir Shah	[phone]	Richard Pulik	[phone]
Pierre-Michel Bringer	[phone]	Sloan Pavsner	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]
e-mail: [e-mail]		e-mail: [e-mail]